Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Q Eichacker

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
BMJ (Clinical Research Ed.)|February 25, 2018
Endorsing performance measures is a matter of trustDharmvir S Jaswal, Charles Natanson, Peter Q Eichacker
Annals of Internal Medicine|March 16, 2018
Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1)Dominique J Pepper, Charles Natanson, Peter Q Eichacker
The New England Journal of Medicine|October 20, 2006
Surviving sepsis--practice guidelines, marketing campaigns, and Eli LillyPeter Q Eichacker, Charles Natanson, Robert L Danner
American Journal of Respiratory and Critical Care Medicine|November 11, 2006
Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapyKevin Sherer, Yan Li, Xizhong Cui, et al.
Critical Care Medicine|April 10, 2002
Inhaled nitric oxide: is systemic host defense at risk?Xizhong Cui, Zenaide M N Quezado, Peter Q Eichacker
Expert Opinion on Biological Therapy|June 9, 2007
New insights into the pathogenesis and treatment of anthrax toxin-induced shockYan Li, Kevin Sherer, Xizhong Cui, et al.
Critical Care Medicine|January 25, 2003
Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered questionSteven M Banks, Eric Gerstenberger, Peter Q Eichacker, et al.
Critical Care Medicine|December 22, 2009
Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsisAmisha V Barochia, Xizhong Cui, Charles Natanson, et al.
Critical Care Medicine|January 11, 2005
The efficacy of drotrecogin alfa depends on severity of illnessKatherine J Deans, Peter C Minneci, Peter Q Eichacker, et al.
Expert Opinion on Drug Metabolism & Toxicology|February 18, 2011
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studiesAmisha Barochia, Steven Solomon, Xizhong Cui, et al.
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
BMJ (Clinical Research Ed.)|February 25, 2018
Endorsing performance measures is a matter of trustDharmvir S Jaswal, Charles Natanson, Peter Q Eichacker
Annals of Internal Medicine|March 16, 2018
Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1)Dominique J Pepper, Charles Natanson, Peter Q Eichacker
The New England Journal of Medicine|October 20, 2006
Surviving sepsis--practice guidelines, marketing campaigns, and Eli LillyPeter Q Eichacker, Charles Natanson, Robert L Danner
American Journal of Respiratory and Critical Care Medicine|November 11, 2006
Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapyKevin Sherer, Yan Li, Xizhong Cui, et al.
Critical Care Medicine|April 10, 2002
Inhaled nitric oxide: is systemic host defense at risk?Xizhong Cui, Zenaide M N Quezado, Peter Q Eichacker
Expert Opinion on Biological Therapy|June 9, 2007
New insights into the pathogenesis and treatment of anthrax toxin-induced shockYan Li, Kevin Sherer, Xizhong Cui, et al.
Critical Care Medicine|January 25, 2003
Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered questionSteven M Banks, Eric Gerstenberger, Peter Q Eichacker, et al.
Critical Care Medicine|December 22, 2009
Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsisAmisha V Barochia, Xizhong Cui, Charles Natanson, et al.
Critical Care Medicine|January 11, 2005
The efficacy of drotrecogin alfa depends on severity of illnessKatherine J Deans, Peter C Minneci, Peter Q Eichacker, et al.
Expert Opinion on Drug Metabolism & Toxicology|February 18, 2011
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studiesAmisha Barochia, Steven Solomon, Xizhong Cui, et al.
Pageof 13